Bookmark and Share

Harold C Standiford
 

Harold C Standiford M.D., M.A.C.P.
Academic Title: Clinical Professor
Primary Appointment: Medicine
Additional Title(s): Medical Director for Infection Control and Antimicrobial Effectiveness
HSTANDIFORD@UMM.EDU
Phone: (410) 328-8786
Fax: (410) 328-0089
Lab: (410) 605-7000 Ext 4862 (Antimicrobial Clinical Research Laboratory)

Research Interests

Dr Standiford is the Medical Director for the Infection Control and Antimicrobial Effectiveness. As such, he provides physician oversight for the University of Maryland Medical Center’s antimicrobial stewardship and infection control programs. He is a Master in the American College of Physicians and is a previous governor of Maryland for that organization. He has extensive experience in clinical research relating to antimicrobial combinations and synergy, control of methicillin-resistant S. aureus, endocarditis and HIV.

 

Dr Standiford is the Medical Director of the Antimicrobial Clinical Research Laboratory. The program performs clinical research with a focus on the prevention and treatment of hospital acquired infections and antimicrobial-resistant pathogens. Topics of investigation include central line associated infections, health care associated and community acquired pneumonia, skin and skin structure infections, infections caused by methicillin-resistant S aureus and Clostridium difficile diarrhea. He is an author of over 100 publications, of which the following are a few examples:


Publications

Prevention of Antimicrobial  Resistance and the Effect of Host Factors on Outcome. Antimicrob Agents and    Chemotherapy.37:1334-1342, 1993.

Hafner R, Inderlied CB, Peterson DM, Wright DJ, Standiford HC, Drusano G, Muth K, and the Division of AIDS Treatment Research Initiative Protocol 007 Study Group.  Correlation of Quantitative Bone Marrow and Blood Cultures in AIDS Patients with Disseminated Mycobacterium avium Complex Infection. JID  180:438-47, 1999.

Wong MT, Kauffman CA, Standiford HC, Linden P, Fort G, Fuchs HJ, Porter SB, Wenzel RP and the Ramoplanin VRE Clinical Study Group.  Effective suppression of vancomycin-resistant enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin.  Clin Infect Dis 2001:33:1476-1482.

Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, and Remington J. Worldwide Clinical Safety and Tolerability with Linezolid: Comparitor-Controlled Phase III Experience. Antimicrob Agents Chemother. 2003: 47; 24-31

Wright M.O., Hebden J.N., Harris A.D., Shanholtz C.B., Standiford H.C., Furuno J.P., Perencevich E.N. Aggressive control measures for resistant Acinetobacter baumanii and the impact on acquisition of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) in a medical icu. Infection Control and Epidemiology. 25:167-168. 2004

Wright M.O., Perencevich E.N., Novak C., Hebden J.N., Standiford H.C., Harris A.D. A preliminary assessment of an automated surveillance system for infection control. Infection Control Hosp Epidemiol. 25:325-32. 2004

Harris A.D., Nemoy L., Johnson J.A., Carnahan A.M., Smith D.L., Standiford H., Perencevich E.N. Co-carriage rates of VRE and ESBL-producing bacteria among a cohort of ICU patients: implications for an active surveillance program. Infection Control and Epidemiology. 25:105-108. 2004

Furuno JP, Perencevich EN, Johnson JA, Wright MO, McGregor JC, Nemoy LL, Roghmann M, Standiford HC, Hebden JN, Strauss SM, Harris AD.  Patients at Risk for Vancomycin-Resistant Staphylococcus aureus: Co-colonization with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus.  Emerg Infect Dis. 11: 1539-4, 2005